Zhiwei Zhong | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Dr. Zhiwei Zhong | Medicine and Health Sciences | Best Researcher Award

The Second Affiliated Hospital of Nanchang University | China

Dr. Zhiwei Zhong’s research focuses on molecular oncology, nanomedicine, and biomarker discovery in complex diseases such as pancreatic cancer, hepatocellular carcinoma, thyroid eye disease, and venous thromboembolism. His studies integrate bioinformatics, molecular biology, and nanotechnology to uncover therapeutic targets and diagnostic biomarkers. Zhong has contributed to several high-impact publications in PLOS One, Cancer Cell International, Oncology Reports, Digestive Diseases and Sciences, and SN Applied Sciences. His notable works include identifying key extracellular proteins (EGFR, CD44, and CXCL8) as potential biomarkers in thyroid eye disease, elucidating the regulatory role of lncRNA FTX in suppressing NAFLD progression to hepatocellular carcinoma via Kupffer cell polarization, and exploring nanoparticle-based drug delivery systems for targeted thrombolysis and cancer therapy. He has also investigated tumor suppressor mechanisms involving KLF9 and CHD1L in pancreatic cancer, providing insights into tumor proliferation, invasion, and survival pathways. His research contributions advance the understanding of molecular pathogenesis, precision diagnostics, and targeted nanotherapeutic strategies in human diseases.

Profile: ORCID

Featured Publications

  1. He, S., Nie, H., Yin, X., & Zhong, Z. (2025, April). Identification of key extracellular proteins as the potential biomarkers in thyroid eye disease. PLOS ONE, 20(4), e0322415. https://doi.org/10.1371/journal.pone.0322415

Long Chang | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Dr. Long Chang | Medicine and Health Sciences | Best Researcher Award

Peking Union Medical College Hospital | China

Dr. Long Chang is an accomplished physician and clinical researcher whose career demonstrates excellence in patient care and significant contributions to hematology. He currently serves as an Attending Physician at the Department of Hematology, Peking Union Medical College Hospital, Beijing, China, building upon his medical training at Peking Union Medical College, Tsinghua University. His research focuses on rare hematologic disorders, particularly myeloproliferative neoplasms and histiocytic diseases, with emphasis on improving diagnostic precision, expanding therapeutic strategies, and enhancing patient outcomes. According to Scopus (Author ID: 57225110413), Dr. Long Chang has authored 39 publications, which have collectively received 165 citations across 152 documents, reflecting the impact of his work, and holds an h-index of 6. He has published influential studies in leading journals including Leukemia, EClinicalMedicine, Oncologist, and Orphanet Journal of Rare Diseases. His work has advanced treatment options for Rosai-Dorfman disease and Langerhans cell histiocytosis while also providing novel insights into gamma heavy chain disease. Notably, his clinical trials have introduced promising approaches such as low-dose cytarabine and novel immunomodulatory therapies, offering alternatives for conditions with limited treatments. Beyond publications, Dr. Long Chang demonstrates commitment to translational medicine by bridging molecular research with patient-centered care. Recognized by peers for his rigor, innovation, and leadership, he has progressed from Resident and Chief Resident to Attending Physician, reflecting both clinical expertise and academic excellence. With impactful contributions influencing practice worldwide, Dr. Long Chang exemplifies the qualities of a dedicated physician-scientist whose work continues to advance the frontiers of hematology.

Profile: Scopus

Featured Publications

  • Chang, L., Zhou, D. B., & Cao, X. X. (2023). Gamma heavy chain disease: A retrospective analysis of 6 cases. Orphanet Journal of Rare Diseases, 18(1), 77.

  • Chang, L., Qiao, B., Cai, H., et al. (2023). Clinical phenotypes, molecular analysis, and outcomes of patients with Rosai-Dorfman disease. Leukemia, 37(11), 2297–2300.

  • Chang, L., Lang, M., Lin, H., et al. (2024). Phase 2 study using low dose cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis. Leukemia, 38(4), 803–809.

  • Chang, L., Lang, M., Liu, T., et al. (2024). Lenalidomide and dexamethasone for Rosai-Dorfman disease: A single arm, single center, prospective phase 2 study. EClinicalMedicine, 73, 102685.

  • Chang, L., Cai, H. C., Lang, M., et al. (2024). Liver involvement with Langerhans cell histiocytosis in adults. The Oncologist. Advance online publication.

Zhechun Wu | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Mr. Zhechun Wu | Medicine and Health Sciences | Best Researcher Award

Chaoyang Hospital | China

Mr. Zhechun Wu is a resident physician in the Department of Urology at Beijing Chaoyang Hospital, Capital Medical University, Beijing, China, who has established himself as an emerging clinician–scientist combining medical training with impactful research. He earned his Bachelor of Science degree from Capital Medical University and is currently advancing his clinical expertise through residency while contributing to translational oncology research. His work is focused on prostate cancer, with particular emphasis on identifying therapeutic targets that regulate tumor immunity, a critical area for developing next-generation treatment strategies. Mr. Zhechun Wu has published in reputable international journals, including a recent article in Investigational New Drugs that explored drug targets modulating tumor immune response, a study that has already been cited in related scholarly work, reflecting its scientific significance. His projects are supported by competitive funding from the National Natural Science Foundation of China  and the Beijing Natural Science Foundation, highlighting his ability to secure prestigious grants and deliver research with clinical and academic value. Alongside research, his clinical practice in urology, oncology, and kidney transplantation strengthens his understanding of patient-centered challenges, allowing him to align laboratory findings with real-world medical needs. This dual role as physician and researcher equips him to contribute to both advancing cancer therapeutics and improving clinical outcomes, establishing a foundation for future leadership in medical innovation and academic research.

Profile: ORCID

Featured Publications

Zhang, Y., Qiu, X., Wu, Z., Li, Y., Shen, X., Wu, J., Cao, P., Sun, Z., & Wang, W. (2025). Comprehensive analysis of the association between volatile organic compound pollutants and chronic kidney disease in hypertensive populations: Insights from multi-omics approaches and identification of potential therapeutic targets. Environmental Research, 121966.

Wu, Z., Li, S., Li, Y., Wang, Z., & Wang, W. (2025). Identifying potential therapeutic targets for prostate cancer with mediating role in tumor immunity. Discover Oncology, 16, 98.

Wu, Z. (2025). Higher sexual frequency correlated with lowered PSA complex levels in U.S. men over 40 and without prostate conditions: A nationwide cross-sectional study. The Journal of Sexual Medicine.

Andrej Sirek | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Dr. Andrej Sirek | Medicine and Health Sciences | Best Researcher Award

University Hospital Basel | Switzerland

Dr. Andrej Sirek is a dedicated Pathology Resident at the University Hospital Basel, Institute of Medical Genetics and Pathology, where he is actively shaping his career at the intersection of clinical diagnostics and medical research. With his educational foundation built in leading European institutions, Dr. Andrej Sirek has developed a strong grounding in medical genetics, histopathology, and laboratory sciences, which now supports his dual role as both clinician and researcher. His residency provides him with exposure to complex pathology cases while also allowing him to engage in research that seeks to bridge genetic profiling and diagnostic pathology, with the long-term aim of contributing to precision medicine and early disease detection. Currently, he has completed one research project and is progressing with another, both expected to yield indexed publications in the near future. Despite being at an early stage of his academic career, his commitment to innovation in pathology has already been recognized with a nomination for the Best Researcher Award. He maintains active membership in several professional organizations, including SGPATH, ÖGPATH, SGZ, and ESP, which strengthens his global collaborations and engagement with the wider pathology community. While he has yet to publish peer-reviewed articles, his ongoing research demonstrates his potential to make impactful contributions to the field. His academic and professional journey underscores the promise of a new generation of clinician-scientists who integrate advanced diagnostic techniques with research innovation to improve patient care. Dr. Andrej Sirek’s trajectory highlights his dedication, scholarly potential, and commitment to excellence in pathology and medical genetics.

Profile: ORCID

Featured Publications

Dr. Andrej Sirek has contributed to impactful research in pathology, focusing on diagnostic innovations, tumor biology, and clinicopathological correlations. Key recent publications include:

Sirek, A., Hench, I. B., Hench, J., Alborelli, I., Gross, M. W., Jakscha, J., Schaller, P., Nagel, G., Baumhoer, D., & Tzankov, A. (2025). Recurrent clonal radiotherapy-associated fibroepithelial polyp of the pharynx: Do low grade radiogenic stromal tumours exist? Case report.

Sobottka, B., Vetter, V., Banaei-Esfahani, A., Nowak, M., Lorch, A., Sirek, A., Mertz, K. D., Brunelli, M., Berthold, D., de Leval, L., et al. (2024). Immune phenotype-genotype associations in primary clear cell renal cell carcinoma and matched metastatic tissue.

Yijun Zheng | Medicine | Best Researcher Award

Published on by Forensic Scientist

Mr. Yijun Zheng | Medicine | Best Researcher Award

The Second Hospital & Clinical Medical School, Lanzhou University | China

Dr. Zheng Yijun is a dedicated medical researcher currently pursuing a PhD in Surgery at Lanzhou University. With a strong focus on the pharmacological actions of traditional Chinese medicine in cancer treatment, particularly gastric cancer, he has contributed to multiple papers, including two independent SCI publications. Dr. Zheng also serves as a reviewer for high-impact journals like Frontiers in Medicine and International Journal of Clinical Practice. He is actively involved in projects funded by the National Natural Science Foundation of China and collaborates on key provincial research initiatives.

Professional profile👤

Scopus

Strengths for the Awards✨

  • Strong Research Focus: Zheng has a clear focus on the prevention and treatment of gastric cancer through traditional Chinese medicine, a significant and relevant area of study in modern healthcare.

  • Academic Contributions: Zheng has independently authored two SCI papers, one of which has achieved a high citation rate, highlighting the impact of their work in the academic community.

  • Collaborative Research: Zheng has been involved in eight research projects, including two funded by the National Natural Science Foundation of China, which demonstrates involvement in high-impact research.

  • Peer Review Contributions: Serving as a reviewer for reputable journals such as SCI and Frontiers in Medicine showcases the recognition of Zheng’s expertise and their ability to contribute to the broader academic community.

  • Zheng Yijun demonstrates strong academic research in a promising and highly relevant field. With a focus on traditional Chinese medicine for cancer treatment, significant publications, and involvement in prestigious research projects, Zheng is well-positioned for consideration for the “Best Researcher Award.” However, expanding the breadth of their research network, increasing publication output, and gaining editorial experience would help to further solidify their candidacy for this award.

Education 🎓

Dr. Zheng is currently enrolled in the PhD program in Surgery at Lanzhou University. His academic journey is complemented by his extensive participation in research, including a review of Astragalus Polysaccharide’s pharmacological effects, published in Frontiers in Pharmacology. He has independently authored SCI papers that contribute to the field of traditional medicine’s role in cancer treatment.

Experience 💼

Dr. Zheng has participated in over eight research projects, two of which were funded by the National Natural Science Foundation of China. His work spans across the investigation of gastric cancer treatment and the pharmacological effects of traditional Chinese medicine. Additionally, Dr. Zheng has served as a reviewer for multiple high-impact journals, solidifying his expertise and credibility in the field.

Research Interest On Medicine 🔬

Dr. Zheng’s primary research interest is in the prevention and treatment of gastric cancer through traditional Chinese medicine. His research aims to provide a theoretical foundation for incorporating traditional medicine in cancer therapy, with a specific focus on polysaccharides and their pharmacological actions in tumor treatment.

Award 🏆

Dr. Zheng is a nominee for the Best Researcher Award at the Forensic Scientist Awards, due to his significant contributions to the field of medical research, particularly in the application of traditional Chinese medicine for tumor treatment. His innovative work and high citation rate highlight his impact in medical research.

Publications 📚

  1. Zheng Y, Ren W, Zhang L, Zhang Y, Liu D, Liu Y. “A Review of the Pharmacological Action of Astragalus Polysaccharide.” Front Pharmacol. 2020 Mar 24; 11:349. Link

    • Cited by: 348 articles (SCI citation)

  2. Zheng Y, Zhang Y, Wang Z, Guo X, Zhang L, Zhang Y. “Multiple data sets to explore the key molecules and mechanism of lymph node metastasis in gastric cancer.” Discov Oncol. 2025 Apr 24; 16(1):606. Link

    • Cited by: 98 articles (SCI citation)

Conclusion 🌍

Dr. Zheng Yijun is an emerging leader in the field of medical research, particularly in the application of traditional Chinese medicine for cancer treatment. His dedication to advancing the understanding of gastric cancer and its treatment methods has already resulted in significant publications and recognition. As a nominee for the Best Researcher Award, his future in medical research looks promising, with continued contributions to the development of effective cancer therapies.

Mario Troisi | Medicine | Excellence in Innovation

Published on by Forensic Scientist

Dr. Mario Troisi | Medicine | Excellence in Innovation

MD | University of Naples Federico II | Italy

Mario Troisi, MD, is an accomplished ophthalmologist and senior resident at the University of Naples Federico II, Italy. He graduated with distinction from the University of Salerno in Medicine and Surgery (110/110 cum laude). Dr. Troisi specializes in ocular surface diseases and corneal surgeries and has participated in numerous prestigious international fellowships, including a corneal fellowship at the University of Brescia and a cataract surgery program in Egypt. A prolific researcher and speaker, he has presented at over 30 national and international conferences. In 2024, Dr. Troisi received the ESCRS Trainee Bursary and the EVER Andrzej Grzybowski Award, highlighting his outstanding contributions to ophthalmology.

Profile

Orcid

Scopus

Google Scholar

Strengths for the Awards

  • Innovative Research Contributions:
    • Dr. Troisi has an impressive portfolio of peer-reviewed publications in high-impact journals. His work emphasizes cutting-edge methodologies like scanning electron microscopy (SEM) for ocular surface diseases, offering diagnostic and therapeutic innovations.
    • Topics such as ocular surface health biomarkers, keratitis diagnosis, and dry-eye treatment advancements showcase his forward-thinking research with potential for significant clinical impact.
  • Diverse Clinical Expertise:
    • His experience spans ophthalmology subspecialties, including cataract surgery, ocular surface diseases, and advanced imaging techniques like SD-OCT and fluorescein angiography.
    • He has engaged in multiple surgical fellowships and clinical trials, demonstrating hands-on application of his research.
  • Recognition and Awards:
    • Dr. Troisi has won prestigious accolades, such as the ESCRS Trainee Bursary and the Andrzej Grzybowski EVER Award in 2024. These reflect his contributions to ophthalmology and innovative research initiatives.
    • His active participation in international conferences as a speaker, presenter, and award finalist further highlights his ability to disseminate knowledge and inspire innovation.
  • Multidisciplinary Education:
    • His educational qualifications, including Master’s degrees in Aesthetic Medicine and Biostatistics, demonstrate a strong foundation in both clinical practice and statistical rigor—critical for conducting impactful research.

Education 🎓📚

Dr. Troisi’s academic journey began with a Scientific High School Diploma, achieved with honors in 2012. He earned his Master’s degree in Medicine and Surgery at the University of Salerno in 2019 (110/110 cum laude). His global outlook led him to an exchange program at Ivane Javakhishvili State University in Georgia. Furthering his expertise, he pursued residencies in ophthalmology, advanced surgical fellowships, and master’s degrees in aesthetic medicine (2023) and biostatistics for clinical research (2024). He also completed specialized training in ophthalmic echography and clinical cornea fellowships.

Professional Experience 💼

Since 2020, Dr. Troisi has worked as a medical practitioner across Salerno and Naples, Italy. His expertise spans internal medicine, ophthalmology, and emergency care. Notably, he contributed to local COVID-19 vaccination campaigns and gained hands-on surgical experience in cataract surgery, corneal cross-linking, and intravitreal injections. Currently, he is a senior resident at the University of Naples Federico II Eye Clinic, specializing in ocular surface diseases and advanced surgical interventions.

Research Interests On Medicine 🔬

Dr. Troisi is deeply involved in research on ocular surface diseases, corneal pathologies, and innovative ophthalmic treatments. His work utilizes advanced techniques such as scanning electron microscopy (SEM) to analyze conjunctival microvilli and evaluate new tear substitutes. His research focuses on clinical trials and translational medicine to improve patient outcomes in ophthalmology.

Awards and Recognitions 🏆🌟

Dr. Troisi has received multiple accolades for his contributions to ophthalmology. In 2024, he won the ESCRS Trainee Bursary and the EVER Andrzej Grzybowski Award. Additionally, his photography and research presentations have been recognized at international conferences, such as winning the “Eye Beyond the Surface” competition at the 27th EVER Congress.

Publications 📑📘

  • Comparative evaluation of antimicrobial, antiamoebic, and antiviral efficacy of ophthalmic formulations
    • Authors: C. Caruso, D. Eletto, A. Tosco, M. Pannetta, F. Scarinci, M. Troisi, A. Porta
    • Year: 2022
    • Citations: 12
  • Ocular surface infection by SARS-CoV-2 in COVID-19 pneumonia patients admitted to sub-intensive unit: preliminary results
    • Authors: M. Troisi, C. Zannella, S. Troisi, M. De Bernardo, M. Galdiero, G. Franci, …
    • Year: 2022
    • Citations: 12
  • Tear liquid for predictive diagnosis of Alzheimer’s disease
    • Authors: S. Del Prete, D. Marasco, R. Sabetta, A. Del Prete, F. Z. Marino, R. Franco, …
    • Year: 2021
    • Citations: 10
  • Scanning Electron Microscopy of Conjunctival Scraping: Our Experience in the Diagnosis of Infectious Keratitis with Negative Culture Tests
    • Authors: M. Troisi, S. Del Prete, S. Troisi, D. Marasco, C. Costagliola
    • Year: 2023
    • Citations: 5
  • Correlative microscopy (CLEM) of tarsal conjunctival scraping: A new opportunity in the diagnosis of microbial keratitis
    • Authors: M. Troisi, S. Del Prete, S. Troisi, D. Marasco, C. Costagliola
    • Year: 2024
    • Citations: 3
  • Utility of Scanning Electron Microscopy (SEM) for Suspected Microbial Keratoconjunctivitis Unresponsive to Broad-Spectrum Antibiotic Therapy
    • Authors: M. Troisi, S. Del Prete, S. Troisi, M. V. Turco, V. Turco
    • Year: 2023
    • Citations: 3
  • Scanning Electron Microscopy (SEM) Evaluation of the Ultrastructural Effects on Conjunctival Epithelial Cells of a New Multiple-Action Artificial Tear Containing Cross-Linked Hyaluronic Acid
    • Authors: M. Troisi, S. Del Prete, S. Troisi, D. Marasco, M. Rinaldi, C. Costagliola
    • Year: 2024
    • Citations: 2
  • Scanning electron microscopy (SEM) of conjunctival scraping for the diagnosis of atypical cases of Acanthamoeba in culture-negative keratoconjunctivitis
    • Authors: M. Troisi, S. Del Prete, S. Troisi, D. Marasco, C. Costagliola
    • Year: 2024
    • Citations: 2
  • Compatibility of a New Ocular Surface Dye with Disposable and Bi-Weekly Soft Contact Lenses: An Experimental Study
    • Authors: M. Troisi, C. Caruso, L. D’Andrea, M. Rinaldi, R. Piscopo, S. Troisi, …
    • Year: 2024
    • Citations: 2
  • Corneal collagen cross-linking in patients with keratoconus from the Dresden protocol to customized solutions: theoretical basis
    • Authors: C. Caruso, L. D’Andrea, M. Troisi, M. Rinaldi, R. Piscopo, S. Troisi, …
    • Year: 2024
    • Citations: 2

Awards and Presentations🏅

Dr. Troisi has delivered over 30 presentations at esteemed conferences:

  • “SEM Insights into Ocular Surface and Dry Eye Management” – Finalist, Clinical Case Competition, European Dry Eye Society, 2024.
  • “Pathological Alterations of Microvilli Structure” – Winner of the EVER Scientific Photography Competition, 2024.
  • “The Role of Scanning Electron Microscopy in Acanthamoeba Diagnosis” – ESCRS, 2024.

Conclusion 🌍

Dr. Mario Troisi’s dedication to ophthalmology is evident in his clinical expertise, research contributions, and academic achievements. His innovative approach to ocular surface diseases and commitment to advancing medical knowledge position him as a rising leader in the field.